Hua Medicine (Shanghai) Ltd.

HKSE 2552.HK

Hua Medicine (Shanghai) Ltd. Price to Sales Ratio (P/S) on January 14, 2025: 15.29

Hua Medicine (Shanghai) Ltd. Price to Sales Ratio (P/S) is 15.29 on January 14, 2025, a -40.14% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Hua Medicine (Shanghai) Ltd. 52-week high Price to Sales Ratio (P/S) is 25.54 on January 15, 2024, which is 67.06% above the current Price to Sales Ratio (P/S).
Hua Medicine (Shanghai) Ltd. 52-week low Price to Sales Ratio (P/S) is 12.58 on September 03, 2024, which is -17.72% below the current Price to Sales Ratio (P/S).
Hua Medicine (Shanghai) Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 17.35.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

HKSE: 2552.HK

Hua Medicine (Shanghai) Ltd.

CEO	Dr. Li Chen Ph.D.
IPO Date	Sept. 14, 2018
Location	China
Headquarters	Building A
Employees	172
Sector	Health Care
Industries Pharmaceuticals Clinical Trials

Description

Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.

Key trends

Past 5 years